Altimmune, Inc.

ALT Nasdaq SEC CIK 1326190
Follow Altimmune Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$31.6M −66.2% vs same quarter last year
EPS, diluted −$0.15 +28.6% vs same quarter last year
Operating cash flow −$37.7M −217.3% vs same quarter last year
Operating income −$35.7M −71.2% vs same quarter last year
Revenue by quarter
$5K
$5K
$5K
$5K
$26K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$41K−$88.1M
FY24$20K−$95.1M
FY23$426K−$88.4M
FY22-−$84.7M
FY21$4.4M−$97.1M
FY20$8.2M−$49M
FY19$5.8M−$20.5M
FY18$10.3M−$39.2M
FY17$10.7M−$46.4M
FY16$3.2M-
FY15-−$3.4M
FY14-−$10M
FY13-−$11.7M
FY12-−$4.9M
FY11$24.3M−$3.8M
MarginsShare of revenue
  • Operating margin
  • Net margin
−600000%−400000%−200000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−230461%−214861%
FY24−515860%−475295%
FY23−22518.5%−20762.2%
FY22--
FY21−2197.4%−2201.4%
FY20−669.5%−599.2%
FY19−370%−353.7%
FY18−414.6%−379.2%
FY17−484.7%−432.3%
FY16−342.7%-
FY15--
FY14--
FY13--
FY12--
FY11−48.3%−15.6%
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$67.5M
FY24-
FY23−$75.9M
FY22−$62.7M
FY21−$90.4M
FY20−$34.5M
FY19−$9.6M
FY18−$10.4M
FY17−$20.3M
FY16−$6.5M
FY15−$3.3M
FY14−$8.6M
FY13−$7.3M
FY12-
FY11−$7.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Altimmune
  • Healthcare median
−600000%−400000%−200000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAltimmuneHealthcare median
FY25−214861%−30.6%
FY24−475295%−47%
FY23−20762.2%−58%
FY22-−80.4%
FY21−2201.4%−71.9%
FY20−599.2%−62.2%
FY19−353.7%−46.3%
FY18−379.2%−49.6%
FY17−432.3%−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11−15.6%−27.9%